Dr Caroline Forkin from ICON discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
“Globally, great strides have been made in HIV testing and treatment,” states a new whitepaper on the evolution and projected progress of HIV treatments. Including post-exposure prophylaxis (PEP), there are a range of antiretroviral therapies available at present to treat HIV. Other recent developments to prevent the spread of HIV include pre-exposure prophylaxis (PrEP), which is the pre-emptive use of antiretroviral therapy by individuals substantially at risk of contracting the virus. However, researchers are still seeking to develop improved therapies and vaccines to combat the virus.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
One of the authors of the whitepaper, Dr Caroline Forkin, Senior Director, Global Research Services at ICON plc, spoke with European Pharmaceutical Review’s Victoria Rees to discuss the landscape of HIV therapies and how they may develop in the future.
Current HIV therapies
“The main focus of HIV treatment to date has been on antiretroviral therapy,” said Forkin. She explained that antiretroviral therapy does not cure HIV, but instead suppresses the virus and slows down its progression in the body, thereby preventing opportunistic infections and AIDS-related deaths.
The range of available antiretroviral therapies has expanded considerably over the years to now include five main classes of antiretrovirals for use in combination to manage HIV but also for use as PEP and PrEP:
NRTIs are the main and first class of antiretroviral therapies developed to treat HIV. Forkin said that zidovudine was the first drug in this class to be approved for the treatment of HIV in 1984, having previously been trialled in cancer. NRTIs prevent HIV-infected cells from replicating by inhibiting the virus’s reverse transcriptase from accurately copying its RNA into DNA.
Protease inhibitors
The second antiretroviral therapy that Forkin discussed was protease inhibitors. She explained that this class of drugs works by disabling protease, an enzyme that HIV needs as part of its reproductive lifecycle, therefore stopping it from multiplying.
“NNRTIs are a great development in many respects,” said Forkin. She noted that when this class of antiretrovirals were introduced they were cheaper than protease inhibitors and opened up the possibility of making antiretroviral therapy more widely available in resource-limited settings, in developing countries that bore – and still bear – a disproportionate impact from HIV. NNRTIs prevent HIV from making copies of itself by binding to and stopping the reverse transcriptase enzyme.
Integrase strand transfer inhibitors (INSTIs)
INSTIs are a more recent development and disable integrase, an enzyme that HIV uses to insert its DNA into human DNA.
Entry inhibitors
Finally, Forkin highlighted the development of entry inhibitors. These block HIV from entering CD4 cells, a target of the virus. These are rarely used as first-line therapy.
“We have come a long way in terms of how we have used these drugs alone and together,” said Forkin. Although initially some of these drugs were administered alone, this has subsequently evolved to dual therapy, followed by highly active antiretroviral therapy (HAART) in the 1990s and what is now referred to as combination antiretroviral therapy. Approaches to treatment initiation have also changed, driven largely by the need for better treatment success in both treatment naïve and treatment experienced individuals. Forkin said that currently there are over 30 antiretroviral drugs available and many of these are now delivered via combination tablets, of which there are more than 20 fixed-dose combination tablets, facilitating administration and adherence.
However, she explained that a lot of the same challenges in HIV treatments still exist, despite the progress that has been made. “We still need to look at what the main challenges are when we look to the more recent developments and also to the future,” said Forkin. These include traditionally high pill burdens; treatment limiting side effects and toxicity; inconvenient dosing; and incomplete virological suppression, which has resulted in decades of problems with antiretroviral resistance. She emphasised that these issues must be taken into consideration for future developments – the focus continues to be on making therapies that are more effective and convenient to improve patient adherence, and on making them more accessible and affordable to ensure more equitable coverage across the globe. At the same time however, the quest continues for an HIV vaccine.
The future landscape of HIV treatment and HIV vaccines
Forkin said that the COVID-19 pandemic has shown how far preventative vaccines have come; the speed at which SARS-CoV-2 vaccines were developed and manufactured has demonstrated the strength of global scientific innovation and what can be achieved when governments, the private sector and the general public galvanise their support behind the scientific community.
We have come a long way in terms of how we have used these drugs alone and together”
However, Forkin believes that HIV vaccine development has been particularly frustrating because relatively little progress has been made since the early 1980s when the virus was first identified and named. Furthermore, because HIV has a highly variable nature, it is easy for the virus to target and impair immune cells and integrate into the host genome early in infection as well as to establish latent infection. Nobody has ever developed an immune response that completely cleared their infection so there is still uncertainty as to what constitutes an appropriate immune response to HIV. According to Forkin, all these issues have led to an increased complexity for HIV vaccine development. Although there has been slow progress, Forkin believes there is now more hope for HIV vaccines.
Considering the progress made with COVID-19 vaccines and the development of messenger RNA (mRNA) vaccines, Forkin said that this bodes well for the potential application of RNA vaccines for HIV. In fact, this is one of the focuses for the International AIDS Vaccine Initiative (IAVI), which is investigating innovative technologies for HIV vaccines, including mRNA and replicating viral vector-based (Vesticular Stomatitis Virus) vaccines.
Another strategy being explored for HIV treatment and vaccines are broadly neutralising antibodies (bNAbs), which Forkin said will likely gain more focus in the wake of COVID-19 vaccine development. These are good candidates for treatment because they have few side effects and can be modified to ensure they remain in the body for a long time. Forkin explained that bNAbs bind to HIV and prevent it from entering the cell, speeding up its elimination. They can also bind to an HIV-infected cell and stimulate immune system components that facilitate the killing of the cell.
Lastly, Forkin touched on cell-based vaccine development and mosaic antigens, which are created from genetic sequences across the whole HIV genome. She said that these are currently being researched and present a promising potential strategy to fight HIV. An example highlighted was Johnson & Johnson’s (J&J) Imbokodo trial of 2017, that evaluated a mosaic-based HIV vaccine regimen. She explained that the use of mosaic immunogens delivered through a viral vector is a more novel approach that has great potential in stopping the spread of HIV. “When we look at these trial designs, focus and content, we can see that they are quite different to some of the early vaccine studies in that they are more innovative and sophisticated,” said Forkin.
“So, we have options. I think we have learned a lot in the last year from the acceleration of vaccine development around SARS-CoV-2. However, HIV is different… and this makes it very challenging to continue to develop new therapies, but also more specifically, to develop a vaccine,” concluded Forkin.
Considering the development made with COVID-19 vaccines and the improvement of messenger RNA (mRNA) vaccines, Forkin stated that this bodes nicely for the capacity software of RNA vaccines for HIV. In fact, that is one of the focuses for the International AIDS Vaccine Initiative (IAVI), that is investigating modern technology for HIV vaccines, along with mRNA and replicating viral vector-based (Vesticular Stomatitis Virus) vaccines.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Considering the development made with COVID-19 vaccines and the improvement of messenger RNA (mRNA) vaccines, Forkin stated that this bodes nicely for the capacity software of RNA vaccines for HIV. In fact, that is one of the focuses for the International AIDS Vaccine Initiative (IAVI), that is investigating modern technology for HIV vaccines, along with mRNA and replicating viral vector-based (Vesticular Stomatitis Virus) vaccines.
Thank You For Sharing a Helpful Article. Great Blog
Thanks for sharing the useful information for us
Really very helpful information about generic medicine.
Good
this blog is very nice its good conten